AU2015333738B2 - Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors - Google Patents
Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors Download PDFInfo
- Publication number
- AU2015333738B2 AU2015333738B2 AU2015333738A AU2015333738A AU2015333738B2 AU 2015333738 B2 AU2015333738 B2 AU 2015333738B2 AU 2015333738 A AU2015333738 A AU 2015333738A AU 2015333738 A AU2015333738 A AU 2015333738A AU 2015333738 B2 AU2015333738 B2 AU 2015333738B2
- Authority
- AU
- Australia
- Prior art keywords
- group
- alkyl
- compound
- aryl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- RIMGKMWYAKQXME-UHFFFAOYSA-N CC(C)(C)OC(N(C)Cc(cccc1NC(c2nc(-c3cncc(O)c3)cnc2N)=O)c1OCCOCCO)=O Chemical compound CC(C)(C)OC(N(C)Cc(cccc1NC(c2nc(-c3cncc(O)c3)cnc2N)=O)c1OCCOCCO)=O RIMGKMWYAKQXME-UHFFFAOYSA-N 0.000 description 2
- FPQOYVWTHFWULJ-UHFFFAOYSA-N CNCc(cccc1NC(c2nc(-c3ccc4cc3)cnc2N)=O)c1OCCOCCOCCN(C)C4=O Chemical compound CNCc(cccc1NC(c2nc(-c3ccc4cc3)cnc2N)=O)c1OCCOCCOCCN(C)C4=O FPQOYVWTHFWULJ-UHFFFAOYSA-N 0.000 description 2
- AQOZXJFINMFIMN-UHFFFAOYSA-N CC(C)(C)OC(N(C)Cc(cccc1NC(c2nc(-c3ccc4cc3)cnc2N)=O)c1OCCOCCOCCN(CCO[Si+](C)(C)C(C)(C)C)S4(=O)=O)=O Chemical compound CC(C)(C)OC(N(C)Cc(cccc1NC(c2nc(-c3ccc4cc3)cnc2N)=O)c1OCCOCCOCCN(CCO[Si+](C)(C)C(C)(C)C)S4(=O)=O)=O AQOZXJFINMFIMN-UHFFFAOYSA-N 0.000 description 1
- UMGDGNGYBUSNGF-UHFFFAOYSA-N CC(C1)C=CC(OCCOCCOCCN)=C1NC(c1nc(-c(cc2)ccc2C(O)=O)cnc1N)=O Chemical compound CC(C1)C=CC(OCCOCCOCCN)=C1NC(c1nc(-c(cc2)ccc2C(O)=O)cnc1N)=O UMGDGNGYBUSNGF-UHFFFAOYSA-N 0.000 description 1
- LIMHVKFZCQGSJD-UHFFFAOYSA-N CC(CCOCCOCCOc(cccc1)c1NC(c1nc(-c2ccc3cc2)cnc1N)=O)S3(=O)=O Chemical compound CC(CCOCCOCCOc(cccc1)c1NC(c1nc(-c2ccc3cc2)cnc1N)=O)S3(=O)=O LIMHVKFZCQGSJD-UHFFFAOYSA-N 0.000 description 1
- FVQSLEHOHZLHMR-UHFFFAOYSA-N CN(C)CNC1CCOCC1 Chemical compound CN(C)CNC1CCOCC1 FVQSLEHOHZLHMR-UHFFFAOYSA-N 0.000 description 1
- RDQQEUNBAYGEGL-UHFFFAOYSA-N CN(CCCOCCOc(cccc1)c1NC(c1nc(-c2ccc3cc2)cnc1N)=O)C3=O Chemical compound CN(CCCOCCOc(cccc1)c1NC(c1nc(-c2ccc3cc2)cnc1N)=O)C3=O RDQQEUNBAYGEGL-UHFFFAOYSA-N 0.000 description 1
- NYHUZAQRABJWFR-UHFFFAOYSA-N CN(Cc(cccc1NC(c2nc(Br)cnc2N)=O)c1OCCOCCOCCO)C(O)=O Chemical compound CN(Cc(cccc1NC(c2nc(Br)cnc2N)=O)c1OCCOCCOCCO)C(O)=O NYHUZAQRABJWFR-UHFFFAOYSA-N 0.000 description 1
- WSLMXVVDIKBORK-UHFFFAOYSA-N CN(Cc(cccc1NC(c2nc(Br)cnc2N)=O)c1OCCOCCOCCOS(C)(=O)=O)C(O)=O Chemical compound CN(Cc(cccc1NC(c2nc(Br)cnc2N)=O)c1OCCOCCOCCOS(C)(=O)=O)C(O)=O WSLMXVVDIKBORK-UHFFFAOYSA-N 0.000 description 1
- YDXJMSXHINGQMT-UHFFFAOYSA-N CNCCOCCOCCOc(cccc1)c1NC(c1nc(-c(cc2)ccc2C(O)=O)cnc1N)=O Chemical compound CNCCOCCOCCOc(cccc1)c1NC(c1nc(-c(cc2)ccc2C(O)=O)cnc1N)=O YDXJMSXHINGQMT-UHFFFAOYSA-N 0.000 description 1
- OMJUARZXULEDAZ-UHFFFAOYSA-N CNCCOCCOCCOc1c(CN(C)C(O)=O)cccc1NC(c1nc(Br)cnc1N)=O Chemical compound CNCCOCCOCCOc1c(CN(C)C(O)=O)cccc1NC(c1nc(Br)cnc1N)=O OMJUARZXULEDAZ-UHFFFAOYSA-N 0.000 description 1
- XFGSQTBCPBMAGQ-UHFFFAOYSA-N CNCc(cccc1NC(c2nc(-c3ccc4cc3)cnc2N)=O)c1OCCOCCOCCN(CCO)S4(=O)=O Chemical compound CNCc(cccc1NC(c2nc(-c3ccc4cc3)cnc2N)=O)c1OCCOCCOCCN(CCO)S4(=O)=O XFGSQTBCPBMAGQ-UHFFFAOYSA-N 0.000 description 1
- LXKXIANBCQWWKV-UHFFFAOYSA-N CNCc(cccc1NC(c2nc(Br)cnc2N)=O)c1OCCOCCOCCN(C)C(c1ccc(B(O)O)cc1)=O Chemical compound CNCc(cccc1NC(c2nc(Br)cnc2N)=O)c1OCCOCCOCCN(C)C(c1ccc(B(O)O)cc1)=O LXKXIANBCQWWKV-UHFFFAOYSA-N 0.000 description 1
- KFBGZPHULWAFKL-UHFFFAOYSA-N CNCc(cccc1[N+]([O-])=O)c1OCCOCCOCCO Chemical compound CNCc(cccc1[N+]([O-])=O)c1OCCOCCOCCO KFBGZPHULWAFKL-UHFFFAOYSA-N 0.000 description 1
- XOOJWPRCDDVGOG-UHFFFAOYSA-O C[SiH+]OCCN(CCOCCOCCOc(cccc1)c1NC(c1nc(-c2ccc3cc2)cnc1N)=O)S3(=O)=O Chemical compound C[SiH+]OCCN(CCOCCOCCOc(cccc1)c1NC(c1nc(-c2ccc3cc2)cnc1N)=O)S3(=O)=O XOOJWPRCDDVGOG-UHFFFAOYSA-O 0.000 description 1
- FICDZBUFWGEFCI-UHFFFAOYSA-N Nc1ncc(-c(cc2)ccc2S(N(CCO)CCOCCOCCOc(cccc2)c2N2)(=O)=O)nc1C2=O Chemical compound Nc1ncc(-c(cc2)ccc2S(N(CCO)CCOCCOCCOc(cccc2)c2N2)(=O)=O)nc1C2=O FICDZBUFWGEFCI-UHFFFAOYSA-N 0.000 description 1
- ARKQVAQLGLIPAU-UHFFFAOYSA-N OB(c(cc1)ccc1C(Cl)=O)O Chemical compound OB(c(cc1)ccc1C(Cl)=O)O ARKQVAQLGLIPAU-UHFFFAOYSA-N 0.000 description 1
- PCCVBLBBPRVZAG-UHFFFAOYSA-N [O-][N+](c(cccc1)c1OCCOCCOCCO)=O Chemical compound [O-][N+](c(cccc1)c1OCCOCCOCCO)=O PCCVBLBBPRVZAG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Biomedical Technology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462063176P | 2014-10-13 | 2014-10-13 | |
| US62/063,176 | 2014-10-13 | ||
| US201562104274P | 2015-01-16 | 2015-01-16 | |
| US62/104,274 | 2015-01-16 | ||
| PCT/US2015/055317 WO2016061097A1 (en) | 2014-10-13 | 2015-10-13 | Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015333738A1 AU2015333738A1 (en) | 2017-05-04 |
| AU2015333738B2 true AU2015333738B2 (en) | 2020-03-26 |
Family
ID=55654998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015333738A Active AU2015333738B2 (en) | 2014-10-13 | 2015-10-13 | Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9663535B2 (enExample) |
| EP (1) | EP3207031B1 (enExample) |
| JP (1) | JP6678679B2 (enExample) |
| KR (1) | KR102569226B1 (enExample) |
| CN (1) | CN107108527B (enExample) |
| AU (1) | AU2015333738B2 (enExample) |
| BR (1) | BR112017007708B8 (enExample) |
| CA (1) | CA2963973C (enExample) |
| ES (1) | ES2879441T3 (enExample) |
| IL (1) | IL251595B (enExample) |
| MX (1) | MX389198B (enExample) |
| WO (1) | WO2016061097A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017007708B8 (pt) | 2014-10-13 | 2023-10-24 | Atrin Pharmaceuticals LLC | Composto macrocíclico e composição farmacêutica |
| WO2017180723A1 (en) * | 2016-04-12 | 2017-10-19 | Atrin Pharmaceuticals LLC | Ataxia telengiectasia and rad3-related (atr) inhibitors and methods of their use |
| WO2018218197A2 (en) | 2017-05-26 | 2018-11-29 | Board Of Regents, The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
| HRP20240368T1 (hr) | 2017-07-13 | 2024-08-30 | Board Of Regents, The University Of Texas System | Heterociklički inhibitori atr kinaze |
| JP7290627B2 (ja) | 2017-08-17 | 2023-06-13 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ａｔｒキナーゼの複素環式阻害剤 |
| US11267809B2 (en) | 2017-09-14 | 2022-03-08 | The Board Of Trustees Of The Leland Stanford Junior University | BAF complex modulating compounds and methods of using the same |
| JP7341156B2 (ja) | 2018-03-16 | 2023-09-08 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ａｔｒキナーゼの複素環式阻害剤 |
| CN110357905B (zh) * | 2018-03-26 | 2021-10-01 | 武汉誉祥医药科技有限公司 | 作为蛋白激酶抑制剂的大环类衍生物及其制备方法和用途 |
| WO2020014524A1 (en) | 2018-07-12 | 2020-01-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for reversing hiv latency using baf complex modulating compounds |
| CN110950890B (zh) * | 2018-09-27 | 2022-07-01 | 北京赛林泰医药技术有限公司 | 取代的咪唑并[4,5-c]喹啉大环化合物作为多靶点激酶抑制剂 |
| KR20210097124A (ko) | 2018-10-30 | 2021-08-06 | 리페어 세라퓨틱스 인크. | 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법 |
| KR20220035925A (ko) | 2019-07-22 | 2022-03-22 | 리페어 세라퓨틱스 인크. | Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체 |
| AU2021360636A1 (en) | 2020-10-16 | 2023-06-15 | Shanghai De Novo Pharmatech Co., Ltd. | Triheterocyclic derivative, and pharmaceutical composition and application thereof |
| WO2023201320A1 (en) | 2022-04-14 | 2023-10-19 | Atrin Pharmaceuticals LLC | Atr inhibitors |
| KR20250023494A (ko) | 2022-06-15 | 2025-02-18 | 아스트라제네카 아베 | 암 치료를 위한 병용 요법 |
| WO2025181153A1 (en) | 2024-03-01 | 2025-09-04 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with pi3k alpha inhibitors |
| WO2025229051A1 (en) | 2024-05-03 | 2025-11-06 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with antiandrogen agent |
| WO2025233224A1 (en) | 2024-05-09 | 2025-11-13 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with anti-pd(l)1 therapy |
| WO2026064575A1 (en) | 2024-09-19 | 2026-03-26 | Aprea Therapeutics, Inc. | Methods for treating cancer |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013132376A1 (en) * | 2012-03-06 | 2013-09-12 | Pfizer Inc. | Macrocyclic derivatives for the treatment of proliferative diseases |
| WO2015050989A2 (en) * | 2013-10-01 | 2015-04-09 | Cs Therapeutics Inc. | Macrocyclic compounds for the treatment of proliferative diseases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2476667E (pt) * | 2003-02-26 | 2014-09-18 | Sugen Inc | Compostos de aminoheteroarilo como inibidores da proteína quinase |
| US7163939B2 (en) * | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
| PL3354650T3 (pl) * | 2008-12-19 | 2022-06-13 | Vertex Pharmaceuticals Incorporated | Związki przydatne jako inhibitory kinazy atr |
| JP2013526540A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| WO2012125603A1 (en) * | 2011-03-16 | 2012-09-20 | Cephalon, Inc. | Macrocyclic compounds as alk, fak and jak2 inhibitors |
| EP2836485B1 (en) * | 2012-03-17 | 2018-01-10 | Polyphor Ag | Conformationally constrained, fully synthetic macrocyclic compounds |
| BR112017007708B8 (pt) | 2014-10-13 | 2023-10-24 | Atrin Pharmaceuticals LLC | Composto macrocíclico e composição farmacêutica |
-
2015
- 2015-10-13 BR BR112017007708A patent/BR112017007708B8/pt active Search and Examination
- 2015-10-13 ES ES15850553T patent/ES2879441T3/es active Active
- 2015-10-13 EP EP15850553.7A patent/EP3207031B1/en active Active
- 2015-10-13 US US14/881,680 patent/US9663535B2/en active Active
- 2015-10-13 WO PCT/US2015/055317 patent/WO2016061097A1/en not_active Ceased
- 2015-10-13 JP JP2017538930A patent/JP6678679B2/ja active Active
- 2015-10-13 KR KR1020177012838A patent/KR102569226B1/ko active Active
- 2015-10-13 CA CA2963973A patent/CA2963973C/en active Active
- 2015-10-13 MX MX2017004515A patent/MX389198B/es unknown
- 2015-10-13 AU AU2015333738A patent/AU2015333738B2/en active Active
- 2015-10-13 CN CN201580067182.7A patent/CN107108527B/zh active Active
-
2017
- 2017-04-05 IL IL251595A patent/IL251595B/en unknown
- 2017-04-27 US US15/498,631 patent/US9981989B2/en active Active
-
2018
- 2018-04-12 US US15/951,302 patent/US10196405B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013132376A1 (en) * | 2012-03-06 | 2013-09-12 | Pfizer Inc. | Macrocyclic derivatives for the treatment of proliferative diseases |
| WO2015050989A2 (en) * | 2013-10-01 | 2015-04-09 | Cs Therapeutics Inc. | Macrocyclic compounds for the treatment of proliferative diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017004515A (es) | 2017-10-31 |
| BR112017007708B8 (pt) | 2023-10-24 |
| EP3207031A1 (en) | 2017-08-23 |
| IL251595A0 (en) | 2017-06-29 |
| US9663535B2 (en) | 2017-05-30 |
| JP6678679B2 (ja) | 2020-04-08 |
| ES2879441T3 (es) | 2021-11-22 |
| BR112017007708A2 (pt) | 2017-12-19 |
| MX389198B (es) | 2025-03-20 |
| CA2963973C (en) | 2023-01-10 |
| EP3207031A4 (en) | 2018-02-14 |
| BR112017007708A8 (enExample) | 2017-12-19 |
| BR112017007708B1 (pt) | 2023-07-25 |
| US10196405B2 (en) | 2019-02-05 |
| KR20170082532A (ko) | 2017-07-14 |
| WO2016061097A1 (en) | 2016-04-21 |
| KR102569226B1 (ko) | 2023-08-22 |
| EP3207031B1 (en) | 2021-04-14 |
| AU2015333738A1 (en) | 2017-05-04 |
| CN107108527A (zh) | 2017-08-29 |
| IL251595B (en) | 2022-04-01 |
| JP2017531041A (ja) | 2017-10-19 |
| US20170226130A1 (en) | 2017-08-10 |
| CA2963973A1 (en) | 2016-04-21 |
| US9981989B2 (en) | 2018-05-29 |
| US20160102104A1 (en) | 2016-04-14 |
| CN107108527B (zh) | 2022-08-02 |
| US20180230168A1 (en) | 2018-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10196405B2 (en) | Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors | |
| US11207325B2 (en) | Triazolopyrimidine compounds and uses thereof | |
| CN107922431B (zh) | Hpk1抑制剂及其使用方法 | |
| ES2768678T3 (es) | Compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de la ATR quinasa, su preparación, diferentes formas sólidas y derivados radiomarcados de las mismas | |
| ES2733847T3 (es) | Método para tratar cáncer usando una combinación de inhibidores de CHK1 y ATR | |
| EP3472161B1 (en) | Triazolopyridine compounds and uses thereof | |
| KR20130129244A (ko) | 치환된 6,6-융합된 질소 헤테로환형 화합물 및 이의 용도 | |
| JP2016512816A (ja) | Ａｔｒキナーゼの阻害剤として有用な化合物 | |
| JP2014520161A (ja) | Ａｔｒキナーゼ阻害剤として有用な化合物 | |
| JP2016512815A (ja) | Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 | |
| JP2016512239A (ja) | Ａｔｒキナーゼの阻害剤として有用な化合物 | |
| KR20140084112A (ko) | Ａｔｒ 키나제의 억제제로서 유용한 화합물 | |
| BR112016008452B1 (pt) | Cocristal, composição farmacêutioca, método de preparação do dito co-cristal e uso dos referidos cocristal e composição farmacêutica | |
| JP2013529199A (ja) | Ａｔｒキナーゼ阻害剤として有用な２−アミノピリジン誘導体 | |
| JP2016540773A (ja) | Ａｔｒキナーゼの阻害剤として有用な化合物 | |
| CN103003273A (zh) | 吡唑并吡啶激酶抑制剂 | |
| WO2017180723A1 (en) | Ataxia telengiectasia and rad3-related (atr) inhibitors and methods of their use | |
| HK1235837B (en) | Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors | |
| HK1235837A1 (en) | Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors | |
| HK1239664B (en) | Triazolopyrimidine compounds and uses thereof | |
| HK1239664A1 (en) | Triazolopyrimidine compounds and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |